30,657 Shares in Crispr Therapeutics AG (CRSP) Purchased by JPMorgan Chase & Co.
JPMorgan Chase & Co. bought a new position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 30,657 shares of the company’s stock, valued at approximately $536,000.
Other large investors have also modified their holdings of the company. Wells Fargo & Company MN lifted its holdings in shares of Crispr Therapeutics by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after buying an additional 6,560 shares in the last quarter. Capital Investment Advisory Services LLC purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $193,000. Ark Investment Management LLC purchased a new stake in shares of Crispr Therapeutics in the second quarter worth about $206,000. Moloney Securities Asset Management LLC purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $235,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Crispr Therapeutics in the second quarter worth about $273,000. Hedge funds and other institutional investors own 21.91% of the company’s stock.
In related news, major shareholder Corp /De/ Celgene sold 22,759 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $19.10, for a total value of $434,696.90. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Thomas Woiwode sold 1,700 shares of the firm’s stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $20.21, for a total transaction of $34,357.00. Following the completion of the sale, the director now directly owns 8,218 shares in the company, valued at $166,085.78. The disclosure for this sale can be found here. Insiders sold 2,168,504 shares of company stock worth $42,538,573 over the last ninety days. 39.98% of the stock is currently owned by insiders.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). The company had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The company’s revenue for the quarter was up 54.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.77) earnings per share. analysts predict that Crispr Therapeutics AG will post -2.46 EPS for the current fiscal year.
A number of equities research analysts have recently issued reports on CRSP shares. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. SunTrust Banks reissued a “hold” rating and issued a $16.00 price target on shares of Crispr Therapeutics in a report on Friday, November 10th. BidaskClub downgraded shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Oppenheimer started coverage on shares of Crispr Therapeutics in a report on Thursday, December 7th. They issued a “hold” rating on the stock. Finally, Piper Jaffray Companies started coverage on shares of Crispr Therapeutics in a report on Friday, December 22nd. They issued an “overweight” rating on the stock. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Crispr Therapeutics has a consensus rating of “Buy” and a consensus price target of $22.81.
Crispr Therapeutics Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.